MONEY

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 16:00
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
Read More

Tags:

Previous Article

The Declaration of Independence and current threats to liberal democracy

Next Article

Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivone...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

ACELYRIN, INC. Announces Positive Results from Global P...

Tomas Kauer - Mode... Sep 19, 2024

Saba capital buys $782k of BlackRock Health Sciences Term Trust shares

Saba capital buys $782k of BlackRock Health Sciences Te...

Tomas Kauer - Mode... Oct 1, 2024

Court gives 5 days for X to validate its Brazil legal representative

Court gives 5 days for X to validate its Brazil legal r...

Tomas Kauer - Mode... Sep 22, 2024